Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
Taysha Gene Therapies Inc (NASDAQ: TSHA) closed the day trading at $4.27 down -4.26% from the previous closing price of $4.46. In other words, the price has decreased by -$4.26 from its previous closing price. On the day, 3.75 million shares were traded. TSHA stock price reached its highest trading level at $4.54 during the session, while it also had its lowest trading level at $4.0.
Ratios:
For a better understanding of TSHA, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 12.48 and its Current Ratio is at 12.48. In the meantime, Its Debt-to-Equity ratio is 0.24 whereas as Long-Term Debt/Eq ratio is at 0.23.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Raymond James on October 21, 2025, initiated with a Strong Buy rating and assigned the stock a target price of $13.
On July 11, 2025, BofA Securities started tracking the stock assigning a Buy rating and target price of $8.
On June 27, 2024, BMO Capital Markets started tracking the stock assigning a Outperform rating and target price of $5.BMO Capital Markets initiated its Outperform rating on June 27, 2024, with a $5 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 22 ’25 when Rumana Haque-Ahmed bought 10,770 shares for $2.83 per share.
Nagendran Sukumar sold 200,000 shares of TSHA for $646,000 on Sep 10 ’25. The President and Head of R&D now owns 1,006,439 shares after completing the transaction at $3.23 per share. On Sep 10 ’25, another insider, Nagendran Sukumar, who serves as the Officer of the company, bought 200,000 shares for $3.26 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TSHA now has a Market Capitalization of 1169635712 and an Enterprise Value of 939649728. For the stock, the TTM Price-to-Sale (P/S) ratio is 150.21 while its Price-to-Book (P/B) ratio in mrq is 4.68. Its current Enterprise Value per Revenue stands at 148.914 whereas that against EBITDA is -9.305.
Stock Price History:
The Beta on a monthly basis for TSHA is 1.04, which has changed by 2.2554746 over the last 52 weeks, in comparison to a change of 0.15566266 over the same period for the S&P500. Over the past 52 weeks, TSHA has reached a high of $5.51, while it has fallen to a 52-week low of $1.05. The 50-Day Moving Average of the stock is 8.59%, while the 200-Day Moving Average is calculated to be 65.17%.
Shares Statistics:
Over the past 3-months, TSHA traded about 6.08M shares per day on average, while over the past 10 days, TSHA traded about 3663910 shares per day. A total of 272.73M shares are outstanding, with a floating share count of 222.28M. Insiders hold about 18.52% of the company’s shares, while institutions hold 87.09% stake in the company. Shares short for TSHA as of 1760486400 were 41975904 with a Short Ratio of 6.90, compared to 1757894400 on 43357026. Therefore, it implies a Short% of Shares Outstanding of 41975904 and a Short% of Float of 17.2.
Earnings Estimates
The company has 4 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is -$0.1, with high estimates of -$0.06 and low estimates of -$0.14.
Analysts are recommending an EPS of between -$0.34 and -$0.38 for the fiscal current year, implying an average EPS of -$0.36. EPS for the following year is -$0.44, with 5.0 analysts recommending between -$0.26 and -$0.58.
Revenue Estimates
A total of 11 analysts have provided revenue estimates for TSHA’s current fiscal year. The highest revenue estimate was $8.29M, while the lowest revenue estimate was $4.29M, resulting in an average revenue estimate of $6.16M. In the same quarter a year ago, actual revenue was $8.33M
